The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml

AIDS

Volumn 16, Issue 11, 2002, Pages 1521-1527

  Easterbrook, Philippa J ^a   Ives, Natalie ^a   Waters, Anele ^a   Mullen, Jane ^b   O'Shea, Siobhan ^b   Peters, Barry ^b   Gazzard, Brian G ^c  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral therapy; CD4 response; HIV drug resistance; Intermittent viraemia

Indexed keywords

CD4 ANTIGEN; INDINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CONFIDENCE INTERVAL; DRUG CROSS REACTIVITY; ENZYME ANALYSIS; EVALUATION; FEMALE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION COMPLICATION; KAPLAN MEIER METHOD; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REBOUND; STATISTICAL ANALYSIS; TREATMENT PLANNING; VIREMIA; VIRUS DETECTION; VIRUS LOAD; VIRUS RESISTANCE; ADULT; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MULTICENTER STUDY; MULTIDRUG RESISTANCE; PHYSIOLOGY; VIROLOGY; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMAN; MALE; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD; VIREMIA; VIRUS REPLICATION; HUMANS;

EID: 0037178326     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200207260-00009     Document Type: Article

References (21)

1. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy
2. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
3. Residual HIV-1 RNA in blood plasma of patients taking suppresive highly active antiretroviral therapy
4. Antiretroviral resistance during successful therapy of HIV type 1 infection
5. The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurement
6. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection
7. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy
8. Genetic characterisation of rebounding HIV-1 after cessation of highly active antiretroviral therapy
9. Prevalence and predictive value of intermittent viraemia with combination antiretroviral therapy
10. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy
11. Effects of influenza vaccination in HIV-infected adults: A double-blind, placebo-controlled trial
12. Mechanisms underlying transient relapses ('blips') of plasma HIV RNA in patients on HAART
13. Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple antiretroviral drug therapy
14. Plasma HIV genotypic drug resistance profiles in subjects with stable plasma viraemia of less than 1000 copies/ml for more than 12 months
15. Does HIV suppression below detection limits of 2nd generation PCR assays improve prognosis? An analysis of two cohorts from a large clinical practice using an observational database
16. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy
17. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS trial
18. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
19. Structured treatment interruption in HIV infection
20. Antiretroviral intensification accelerates the decay of the latent reservoir of HIV-1 and increases but does not eliminate ongoing viral replication